Migraine Drugs Market Size, Share & Industry Analysis, By Drug Class (Preventative Treatment, Acute Treatment), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) And Regional Forecast, 2024-2032

Migraine is categorized as a neurological medical condition wherein the individual suffers from throbbing and intense headache. Accompanying symptoms may include vomiting, numbness, nausea difficulty speaking, among others. Migraines are also said to be linked genetically and can affect people of all age groups. The throbbing headache can be induced through various external factors such as stress, alcohol, hormonal changes, and food allergies. Migraines are usually self-manageable. However, certain severe cases require medications such as no-steroidal anti-inflammatory drugs, analgesics, antipsychotics, among various other drugs. Increasing adoption of a sedentary lifestyle has presupposed the younger population to migraine pains. This trend is projected to influence market growth in the coming years positively.

The rising prevalence of neurological disorders like migraine among the younger population owed to a higher sedentary lifestyle is estimated to augment the market growth in the coming years. For instance, according to the Migraine Research Foundation, over one billion people worldwide suffer from migraine attacks. The Foundation also states that over 39 million individuals suffer from this neurological condition in the U.S alone.

However, there is limited awareness regarding migraine, and lack of awareness regarding the proper treatment of the disorder in emerging nations is estimated to hamper the market growth.

Key Market Driver -

Rising prevalence of migraine

Key Market Restraint -

Lower diagnosis and awareness regarding migraine

Market Segmentation:

Globally, the migraine drug market can be categorized into product type, distribution channel, and region. Based on drug class, the market can be bifurcated into preventative treatment and acute treatment. Preventative treatment can be further categorized into ergotamine, analgesics, and triptans. Acute treatment includes calcium channel blockers, beta-blockers, anticonvulsants, antidepressants, anti-serotonergic drugs, and others. Based on administration, the market can be divided into oral, injectable, and others. Based on the segmentation of distribution channels, the market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the Migraine drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

Key Players Covered:

Some of the major companies that are present in the migraine drugs market are Amgen, Abbott Laboratories, Allergan, Eli Lilly, Pfizer, Inc., AstraZeneca, Johnson and Johnson Services, Inc., GlaxoSmithKline, and other prominent players

Key Insights:

• Key Industry Developments – Merger, Acquisitions, and Partnerships


• Key Product Launches


• Key Industry Trends


• Epidemiology of Migraine, Key Regions


• COVID-19 Impact on Migraine drugs Market

Regional Analysis:

Based on region segmentation, the migraine drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold the major market share in 2020. This is influenced by factors such as the higher preference of key players to launch the product in the region, higher accessibility to prescription and over-the-counter drugs, established healthcare system, among others. North America is anticipated to retain its position throughout the forecast duration. Europe, on the other hand, is projected to hold the second-largest share in the market. This is attributed to factors such as favorable reimbursement policies and non-government support groups that help spread awareness regarding migraine and its available treatment options.

Meanwhile, in countries of Asia Pacific, there is limited knowledge regarding various treatment options for migraines. Lower awareness with respect to the severity of migraine disorder is anticipated to be the factor that limited the expansion of the market in the region. However, increasing disposable income in countries such as India and China could favor market growth in the coming years. Latin America, the Middle East, and Africa are projected to hold significantly lower market share in 2020.

To gain extensive insights into the market, Request for Customization

Segmentation

Migraine drugs Market Industry Developments

• In January 2020, the U.S FDA approved the use of ubrogepant manufactured by Allegran. The drug is indicated to treat acute migraine.


• In October 2019, the U.S FDA issued 510(k) marketing authorisation for Reyvow manufactured by Eli Lilly and Company. The medication is indicated to treat migraine in adults over 18. years of age